Protective effect of a protein epitope mimetic (PEM) CCR10 antagonist, POL7085, in an allergic model of asthma

F. Daubeuf, F. Jung, E. Chevalier, N. Frossard (Illkirch, France; Allschwil, Switzerland)

Source: Annual Congress 2011 - Translational models of airway disease
Session: Translational models of airway disease
Session type: Oral Presentation
Number: 4687
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. Daubeuf, F. Jung, E. Chevalier, N. Frossard (Illkirch, France; Allschwil, Switzerland). Protective effect of a protein epitope mimetic (PEM) CCR10 antagonist, POL7085, in an allergic model of asthma. Eur Respir J 2011; 38: Suppl. 55, 4687

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Protective effect of a Protein Epitope Mimetic (PEM) CXCR4 antagonist, POL5551, in an allergic model of asthma
Source: Annual Congress 2010 - Models of airways disease
Year: 2010

Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459
Source: Eur Respir J 2013; 41: 46-52
Year: 2013



The toll-like receptor (TLR) 5 ligand, flagellin, prometes asthma by priming allergic responses to indoor allergens
Source: Annual Congress 2011 - Asthma mechanisms
Year: 2011



Effects of the novel toll-like receptor 7 (TLR7) agonist AZD8848 on allergen-induced responses in patients with mild asthma
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012

PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: a Phase-IIa trial
Source: Virtual Congress 2020 – Cutting edge science: novel molecules and mechanisms of airway diseases
Year: 2020




Effects of treatment with angiotensin-(1-7) on antigen sensitization of murine experimental model of asthma
Source: International Congress 2019 – Modelling and monitoring of airway diseases
Year: 2019

CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge
Source: Eur Respir J 2004; 23: 876-884
Year: 2004



Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma.
Source: International Congress 2019 – Modelling and monitoring of airway diseases
Year: 2019

The effect of a leukotriene antagonist, pranlukast, on allergen-induced airway responses and circulating dendritic cells in subjects with atopic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 414s
Year: 2003

Deletion in macrophage chemokine receptor gene (CCR5) in children with bronchial asthma (BA)
Source: Eur Respir J 2001; 18: Suppl. 33, 450s
Year: 2001

An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse
Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Year: 2013

The effect of anti-IL-33 antibody and soluble ST2 in a murine model of allergic asthma
Source: Annual Congress 2013 –Murine models of lung immunology
Year: 2013

Effect of the leukotriene-receptor antagonists and interval hypoxic trainings (IHT) at children with asthma (BA) and allergic rhinitis (AR)
Source: Annual Congress 2008 - Exercise-induced asthma, acute severe asthma and allergic rhinitis in children
Year: 2008

Alpha-7 nicotinic receptor stimulation reduces airway inflammation in a murine model of asthma
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016

TLR 7/8 agonist resiquimod alleviates murine allergic asthma through IL-27 production and up regulation of B7-H1 on antigen presenting cells
Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions
Year: 2015

Expression of interleukin-4 receptor in bronchial asthma patients treated with specific immunotherapy (SIT)
Source: Eur Respir J 2002; 20: Suppl. 38, 589s
Year: 2002

Inhibition of the inhaled allergen challenge response by the CRTH2 antagonist OC000459 in patients with asthma
Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease
Year: 2010

Efficacy of UR-63325, a new H4 receptor antagonist, in two rodent asthma models
Source: Annual Congress 2010 - Models of airways disease
Year: 2010


Association of genetic variations of CC chemokine receptor-2 (CCR2) with atopic asthma, but not with nonatopic asthma
Source: Annual Congress 2005 - Genetic polymorphisms and molecular mechanisms in asthma pathophysiology
Year: 2005


Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 219s
Year: 2004